A perspective on progress and gaps in HIV prevention science

Patrick F. Kiser, Pedro M M Mesquita, Betsy Herold

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

In the past few years, the transdisciplinary field of HIV prevention has reached several milestones. Topically applied tenofovir gel provided significant protection from sexual transmission of HIV in a large-scale clinical trial and oral Truvada (emtricitabine/tenofovir disoproxil fumarate) was recently approved for preexposure prophylaxis (PrEP) following two successful clinical trials in men and women. These achievements are tempered by the disappointing results of other clinical trials, which highlight the complexities of prevention research. In this perspective, we discuss scientific and developmental gaps for topical chemoprophylaxis of the sexual transmission of HIV, which depends on the complex interactions between the pharmacokinetics and pharmacodynamics of drugs, formulation and delivery systems, anatomic site of transmission, and host mucosal immune defenses. Despite the considerable time and resources devoted to unraveling the initial steps in sexual transmission of HIV, current knowledge is based on animal models and human explanted tissue, which may not fully recapitulate what happens clinically. Understanding these events, including the role that sex hormones, semen, and mucosal secretions play in transmission, and the interplay between innate immunity, the mucosal environment, and drug efficacy is paramount. This drives some of the most pressing questions in the field.

Original languageEnglish (US)
Pages (from-to)1373-1378
Number of pages6
JournalAIDS Research and Human Retroviruses
Volume28
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

Tenofovir
HIV
Clinical Trials
Drug Compounding
Chemoprevention
Gonadal Steroid Hormones
Drug Delivery Systems
Semen
Innate Immunity
Animal Models
Pharmacokinetics
Gels
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Infectious Diseases

Cite this

A perspective on progress and gaps in HIV prevention science. / Kiser, Patrick F.; Mesquita, Pedro M M; Herold, Betsy.

In: AIDS Research and Human Retroviruses, Vol. 28, No. 11, 01.11.2012, p. 1373-1378.

Research output: Contribution to journalArticle

Kiser, Patrick F. ; Mesquita, Pedro M M ; Herold, Betsy. / A perspective on progress and gaps in HIV prevention science. In: AIDS Research and Human Retroviruses. 2012 ; Vol. 28, No. 11. pp. 1373-1378.
@article{9682a1e672664b5984d984d8b84d1e83,
title = "A perspective on progress and gaps in HIV prevention science",
abstract = "In the past few years, the transdisciplinary field of HIV prevention has reached several milestones. Topically applied tenofovir gel provided significant protection from sexual transmission of HIV in a large-scale clinical trial and oral Truvada (emtricitabine/tenofovir disoproxil fumarate) was recently approved for preexposure prophylaxis (PrEP) following two successful clinical trials in men and women. These achievements are tempered by the disappointing results of other clinical trials, which highlight the complexities of prevention research. In this perspective, we discuss scientific and developmental gaps for topical chemoprophylaxis of the sexual transmission of HIV, which depends on the complex interactions between the pharmacokinetics and pharmacodynamics of drugs, formulation and delivery systems, anatomic site of transmission, and host mucosal immune defenses. Despite the considerable time and resources devoted to unraveling the initial steps in sexual transmission of HIV, current knowledge is based on animal models and human explanted tissue, which may not fully recapitulate what happens clinically. Understanding these events, including the role that sex hormones, semen, and mucosal secretions play in transmission, and the interplay between innate immunity, the mucosal environment, and drug efficacy is paramount. This drives some of the most pressing questions in the field.",
author = "Kiser, {Patrick F.} and Mesquita, {Pedro M M} and Betsy Herold",
year = "2012",
month = "11",
day = "1",
doi = "10.1089/aid.2012.0277",
language = "English (US)",
volume = "28",
pages = "1373--1378",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "11",

}

TY - JOUR

T1 - A perspective on progress and gaps in HIV prevention science

AU - Kiser, Patrick F.

AU - Mesquita, Pedro M M

AU - Herold, Betsy

PY - 2012/11/1

Y1 - 2012/11/1

N2 - In the past few years, the transdisciplinary field of HIV prevention has reached several milestones. Topically applied tenofovir gel provided significant protection from sexual transmission of HIV in a large-scale clinical trial and oral Truvada (emtricitabine/tenofovir disoproxil fumarate) was recently approved for preexposure prophylaxis (PrEP) following two successful clinical trials in men and women. These achievements are tempered by the disappointing results of other clinical trials, which highlight the complexities of prevention research. In this perspective, we discuss scientific and developmental gaps for topical chemoprophylaxis of the sexual transmission of HIV, which depends on the complex interactions between the pharmacokinetics and pharmacodynamics of drugs, formulation and delivery systems, anatomic site of transmission, and host mucosal immune defenses. Despite the considerable time and resources devoted to unraveling the initial steps in sexual transmission of HIV, current knowledge is based on animal models and human explanted tissue, which may not fully recapitulate what happens clinically. Understanding these events, including the role that sex hormones, semen, and mucosal secretions play in transmission, and the interplay between innate immunity, the mucosal environment, and drug efficacy is paramount. This drives some of the most pressing questions in the field.

AB - In the past few years, the transdisciplinary field of HIV prevention has reached several milestones. Topically applied tenofovir gel provided significant protection from sexual transmission of HIV in a large-scale clinical trial and oral Truvada (emtricitabine/tenofovir disoproxil fumarate) was recently approved for preexposure prophylaxis (PrEP) following two successful clinical trials in men and women. These achievements are tempered by the disappointing results of other clinical trials, which highlight the complexities of prevention research. In this perspective, we discuss scientific and developmental gaps for topical chemoprophylaxis of the sexual transmission of HIV, which depends on the complex interactions between the pharmacokinetics and pharmacodynamics of drugs, formulation and delivery systems, anatomic site of transmission, and host mucosal immune defenses. Despite the considerable time and resources devoted to unraveling the initial steps in sexual transmission of HIV, current knowledge is based on animal models and human explanted tissue, which may not fully recapitulate what happens clinically. Understanding these events, including the role that sex hormones, semen, and mucosal secretions play in transmission, and the interplay between innate immunity, the mucosal environment, and drug efficacy is paramount. This drives some of the most pressing questions in the field.

UR - http://www.scopus.com/inward/record.url?scp=84868600510&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868600510&partnerID=8YFLogxK

U2 - 10.1089/aid.2012.0277

DO - 10.1089/aid.2012.0277

M3 - Article

VL - 28

SP - 1373

EP - 1378

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 11

ER -